ATA Inc.
ATAI
NSD
Sector: Consumer Defensive
Industry: Education & Training Services
4.38
USD
0.27
(6.57%)
Optionable: Yes Market Cap: 614 M 90-day average vol: 0
Previous close: 4.11 Open: 4.12 Bid: 4.45 Ask: 4.45
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 1,237.90 |
Price per Book TTM ($) | 1.65 |
PE Ratio (TTM) | -2.50 |
Book Value per Share ($) | 2.15 |
5 Year PE Range | -6 , -6.3 |
Returns
7 Day Return | 23.38% | |
1 Month Return | 1.62% | |
3 Month Return | 31.14% | |
1 Year Return | -69.37% | |
3 Year Return | -77.48% | |
5 Year Return | -77.48% | |
YTD Return | -42.60% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 60.99 |
14 Day SMA ($) | 3.98 |
14 Day EMA ($) | 3.99 |
Money Flow Index | 69.30 |
Average True Range | 0.26 |
50 Day SMA ($) | 3.80 |
200 Day SMA ($) | 6.52 |
ADX | 15.96 |
MACD | 0.05 |
Growth
Free Cash Flow QoQ Growth | 0.00% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
Yahoo Finance 2/16/2022
atai Life Sciences to Participate in Upcoming February Investor Conference
Yahoo Finance 2/15/2022
Cathie Wood dabbles with psychedelics (in the stock market that is)
Seeking Alpha 2/9/2022
Dalriada-atai collaborate to discover next-gen therapies for mental health disorders
Seeking Alpha 1/27/2022
Atai Life says FDA gives IND clearance for PCN-101 R-ketamine program
Seeking Alpha 1/12/2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
Yahoo Finance 1/12/2022
atai Life Sciences to Participate in Upcoming January Investor Conference
Yahoo Finance 1/10/2022
Implied Volatility Surging for ATAI Life Sciences (ATAI) Stock Options
Yahoo Finance 12/29/2021
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health
Yahoo Finance 12/23/2021
3 Psychedelic Stocks to Play the Shroom Boom
Yahoo Finance 12/22/2021
Armada Acquisition Corp. I to acquire Rezolve Mobile Engagement Platform in $2bn deal
Yahoo Finance 12/17/2021
Christian Angermayer-backed Australian firm Bionomics soars 78% intraday after U.S. IPO
Seeking Alpha 12/16/2021
Atai Life Sciences’ philanthropic program launches fund for psychedelic research
Seeking Alpha 12/16/2021
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
Yahoo Finance 12/16/2021
Atai Life Sciences announces lock-up extension for over 30% of common stock
Seeking Alpha 12/15/2021
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
Yahoo Finance 12/15/2021
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
Yahoo Finance 12/14/2021
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
Yahoo Finance 12/13/2021
Stocks To Watch: Rivian Earnings, Samsara IPO And Events For Delta, Lowe's And Eli Lilly
Seeking Alpha 12/11/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 56.217
Financials
ATAI Income Statement
Annual
| Invalid date | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|
| Total revenues | 0 | 0 | 20 M | |
| Cost of sales | -6000 | -24000 | -47000 | |
| Gross operating profit | 0 | 0 | 20 M | |
| Selling Gen & administrative expense | 5 M | 81 M | 93 M | |
| Research & development expense | 13 M | 11 M | 48 M | |
| Operating income | -18 M | -92 M | -120 M | |
| floaterest income | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | |
| Other income net | 351000 | -10 M | -16 M | |
| Pre-tax Income (EBT) | -17 M | -102 M | -137 M | |
| Income taxes | 2000 | 305000 | -4 M | |
| Net income from total operations | -24 M | -179 M | -174 M | |
| Minority floaterest | 0 | 0 | 0 | |
| Total net income | -14 M | -170 M | -168 M | |
| Preferred dividends | N/A | N/A | N/A | |
| Net income available for common | -24 M | -179 M | -174 M | |
| Depreciation | 6000 | 24000 | 47000 | |
| Amortization | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -18 M | -92 M | -120 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | |
| Basic EPS total | -0.09 | -1.11 | -1.21 | |
| Diluted EPS total | -0.09 | -1.11 | -1.21 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!